Bristol Myers Squibb to Present Cardiovascular Data at ESC Congress 2024

Bristol Myers Squibb (NYSE: BMY) has announced its participation at the European Society of Cardiology (ESC) Congress in London, England, from August 30 to September 2, 2024. The company will present a range of research findings from its cardiovascular portfolio. The data includes long-term extension studies evaluating the efficacy and safety of CAMZYOS® (mavacamten) for up to 180 weeks in treating New York Heart Association (NYHA) class II-III symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Additionally, findings on ELIQUIS® (apixaban) and milvexian, through collaborations with Pfizer and Johnson & Johnson respectively, will be shared.

Roland Chen, MD, Senior Vice President and Head of Immunology, Cardiovascular & Neuroscience Development at Bristol Myers Squibb, emphasized the company's dedication to improving patient outcomes for those affected by cardiovascular diseases. The company aims to highlight advancements in anticoagulation, thrombosis management, and treatments for obstructive HCM during the congress.

Key presentations will include:
1. Long-term efficacy and safety of CAMZYOS in NYHA class II-III obstructive HCM over nearly 3.5 years, derived from the EXPLORER Ph3 MAVA LTE study.
2. The relationship between pharmacodynamic biomarkers of coagulation and systemic milvexian exposure from the AXIOMATIC-TKR study.
3. Gender and racial differences in clinical outcomes among Medicare beneficiaries with non-valvular atrial fibrillation (NVAF) treated with oral anticoagulants, including ELIQUIS.

Several important abstracts, supported by Bristol Myers Squibb and its collaborations, will also be presented:
- “Assessing the alignment of obstructive hypertrophic cardiomyopathy pharmacological treatments with ESC guidelines in Germany” by Sedaghat-Hamedani.
- “Clinical characteristics and burden of non-obstructive hypertrophic cardiomyopathy: a real-world survey in Italy and Spain” by Lowe.
- “Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study” by Garcia-Pavia.
- Insights into ventricular strain changes in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten from the VALOR-HCM trial, presented by Desai.
- “Gender and racial differences in outcomes among patients with NVAF treated with oral anticoagulants: a real-world evaluation of Medicare beneficiaries” by Atreja.
- “Incidence of cardiovascular conditions in patients admitted to hospital with and without COVID-19 in the South-East of Scotland” by Bulgara.
- “GUARD-AF - Reducing stroke by screening for undiagnosed atrial fibrillation in elderly individuals” by Lopes.
- “Characterisation of the pharmacokinetic and pharmacodynamic relationship of milvexian in total knee replacement patients” by Zhou.

CAMZYOS is a selective cardiac myosin inhibitor approved in the U.S. for treating symptomatic NYHA class II-III obstructive HCM in adults, enhancing functional capacity and symptom relief. It has received regulatory approvals across several countries.

ELIQUIS, a selective Factor Xa inhibitor, is approved in the U.S. for reducing stroke risk and systemic embolism in patients with NVAF, prophylaxis of deep vein thrombosis (DVT) post-surgery, DVT and pulmonary embolism (PE) treatment, and reducing the risk of recurrent DVT and PE. Developed and commercialized by Bristol Myers Squibb-Pfizer Alliance, ELIQUIS continues to be a vital medication in the cardiovascular domain.

The ESC Congress 2024 presents an opportunity for Bristol Myers Squibb to showcase its ongoing efforts and significant strides in cardiovascular research and treatment, reaffirming its commitment to addressing unmet needs in this critical field.